Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-07
DOI
10.3389/fimmu.2021.661737
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
- (2020) P. Nathan et al. ANNALS OF ONCOLOGY
- Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma
- (2020) Reinhard Dummer et al. JAMA Oncology
- Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
- (2020) H. Gogas et al. ANNALS OF ONCOLOGY
- Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
- (2020) Emily J. Lelliott et al. Cancer Immunology Research
- Targeting the ERK Signaling Pathway in Melanoma
- (2019) Paola Savoia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- BRAF targeting sensitizes resistant melanoma to cytotoxic T cells
- (2019) Cigdem Atay et al. CLINICAL CANCER RESEARCH
- Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
- (2019) Melvyn T. Chow et al. IMMUNITY
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
- (2019) Chune Yu et al. Frontiers in Immunology
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
- (2019) Imran G. House et al. CLINICAL CANCER RESEARCH
- Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
- (2019) Antoni Ribas et al. CLINICAL CANCER RESEARCH
- Trends in clinical development for PD-1/PD-L1 inhibitors
- (2019) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
- (2019) Qing-Qing Chai et al. Frontiers in Pharmacology
- Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
- (2019) Dan A. Erkes et al. Cancer Discovery
- Development of encorafenib for BRAF-mutated advanced melanoma
- (2018) Peter Koelblinger et al. CURRENT OPINION IN ONCOLOGY
- Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
- (2018) Claire A. Martin et al. INTERNATIONAL JOURNAL OF CANCER
- Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
- (2018) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitors of the PD-1 Pathway in Tumor Therapy
- (2018) Martin W. LaFleur et al. JOURNAL OF IMMUNOLOGY
- ERK Inhibition: A New Front in the War against MAPK Pathway–Driven Cancers?
- (2018) Inna Smalley et al. Cancer Discovery
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
- (2018) Meghan J. Mooradian et al. OncoImmunology
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
- (2018) Xin Jin et al. MOLECULAR CELL
- Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
- (2018) Danbee Ha et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
- (2017) Ester Simeone et al. OncoImmunology
- Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
- (2016) A. Yoshida et al. CANCER RESEARCH
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
- (2016) Georgina V Long et al. LANCET ONCOLOGY
- Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways
- (2016) Amanda Tse et al. PLoS One
- Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
- (2016) Giuseppe Argenziano et al. OncoTargets and Therapy
- Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
- (2016) Michael S. Lee et al. Oncotarget
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
- (2016) Marcel A. Deken et al. OncoImmunology
- Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
- (2016) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
- (2015) T. Wang et al. CLINICAL CANCER RESEARCH
- Overall survival in patients with metastatic melanoma
- (2015) Xue Song et al. CURRENT MEDICAL RESEARCH AND OPINION
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
- (2015) David R. Minor et al. Pigment Cell & Melanoma Research
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Anti–PD-1 Therapy in Melanoma
- (2015) Blanca Homet Moreno et al. SEMINARS IN ONCOLOGY
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
- (2015) Blanca Homet Moreno et al. OncoImmunology
- Vemurafenib and ipilimumab: A promising combination? Results of a case series
- (2015) Jessica C. Hassel et al. OncoImmunology
- Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
- (2014) John C Castle et al. BMC GENOMICS
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- (2014) Allison Ackerman et al. CANCER
- Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged
- (2014) Paul B. Chapman et al. CANCER CELL
- Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
- (2014) L. Ferrari de Andrade et al. CANCER RESEARCH
- Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
- (2014) K. M. Ilieva et al. MOLECULAR CANCER THERAPEUTICS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Cellular senescence: from physiology to pathology
- (2014) Daniel Muñoz-Espín et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
- (2014) L. J. Vella et al. Cancer Immunology Research
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
- (2013) K. E. Sheppard et al. CLINICAL CANCER RESEARCH
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
- (2013) M. K. Callahan et al. Cancer Immunology Research
- Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
- (2013) Bishu Sapkota et al. OncoImmunology
- Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
- (2012) X. Tai et al. BLOOD
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Role of Cdk4 in lymphocyte function and allergen response
- (2011) Yu Hua Chow et al. CELL CYCLE
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
- (2011) E. R. Cantwell-Dorris et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
- (2010) Jean-Philippe Coppé et al. Annual Review of Pathology-Mechanisms of Disease
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
- (2010) Yohannes Mebratu et al. CELL CYCLE
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanocytes are deficient in repair of oxidative DNA damage and UV-induced photoproducts
- (2010) H.-T. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epidemiology of invasive cutaneous melanoma
- (2009) R. M. MacKie et al. ANNALS OF ONCOLOGY
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search